Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.
It is a $76.8B healthcare company. Revenue grew 9.3% over the last year, it keeps 28¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 17.8× earnings — around the middle of its own history.
- Website
- regeneron.com
- Location
- Tarrytown, NY
- Employees
- 15 410
- Sector
- Healthcare
- Founded
- 1988
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong profitability, health and moat; Growth lags behind.
Valuation56
- P/E vs own history55th pct · 12/25
- FCF yield4.9% · 12/25
- P/S4.9x · 20/25
- EV/EBITDA17.6x · 12/25
Growth37
- Revenue CAGR-2.8% · 0/25
- Net income CAGR-13.6% · 0/25
- EPS CAGR ~5Y6.3% · 12/25
- Fwd implied growth32.7% · 25/25
Profitability77
- ROIC18.3% · 20/25
- ROE13.8% · 12/25
- Net margin27.9% · 25/25
- Operating margin24.7% · 20/25
Health75
- Altman Zn/a · 0/25
- Current ratio3.34 · 25/25
- Interest coverage50.0x · 25/25
- Net cash / debtNet cash · 25/25
Quality69
- Piotroski F5/9 · 15/25
- Beneish M-2.50 · 20/25
- FCF conversion87% · 22/25
- Margin stabilityσ 9.2% · 12/25
Moat100
- ROIC >12% years9/10 yrs · 25/25
- Median gross margin86.7% · 25/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst 18.4% · 25/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- 2023AcquisitionRegeneron announced it would acquire Decibel Therapeutics
- FY2021FinancialRevenue crossed $10B$16.1B for the year
- FY2021FinancialBest year on record$8.08B net income
- 2018ProductLibtayo was approved by the FDA in September 2018. * Inmazeb (atoltivimab/maftivimab/odesivimab) is a drug made of…
- FY2016FinancialProfitable every year on record10 consecutive profitable years in our data
- FY2016FinancialRevenue already above $1B$4.86B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
- 1988FoundedThe company was founded in 1988
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (86.0%)
- Strongly profitable — 27.9% net margin
- Strong cash conversion — FCF is 24.2% of revenue
- Net cash position after subtracting debt from cash
- Interest covered 50.0× by operating earnings
Watch-outs
Nothing stands out as a concern in the available data.
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+9.3% YoY
- Profitable — makes more than it spends$4.33B TTM
- Profit growing — earnings are higher than last year+2.8% YoY
- Generates cash — cash left after running and investing$3.76B TTM
- Debt under control — could handle its obligationsmore cash than debt
- Established company — not a micro-cap — lower blow-up risk$76.8B market cap
- Not printing shares — share count not ballooning — you keep your slice-5.6% shares over ~5y
- Proven track record — years of profitability behind it10/10 profitable years
- Financially stable — balance sheet not near distresshealth score 50/100
- Pays a dividend — returns cash to shareholdersyield 0.49%
- Valuation not extreme — price not wildly above earningsP/E 17.8
Peer comparisonRegeneron Pharmaceuticals Inc vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| REGN this company | $76.8B | 17.8 | +9.3% | 27.9% | Mixed |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: REGN vs LLY · REGN vs JNJ · REGN vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/REGN
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of REGN on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $745.55 · market cap $76.8B.